Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Glyoxalase I Glu111Ala polymorphism in patients with breast cancer.
Germanová A, Germanová A, Tesarová P, Jáchymová M, Zvára K, Zima T, Kalousová M. Germanová A, et al. Among authors: tesarova p. Cancer Invest. 2009 Jul;27(6):655-60. doi: 10.1080/07357900802350822. Cancer Invest. 2009. PMID: 19452310
The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study.
Neven P, Markopoulos C, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P, Barni S, Deschamp V. Neven P, et al. Among authors: tesarova p. Breast. 2014 Aug;23(4):393-9. doi: 10.1016/j.breast.2014.02.009. Epub 2014 Mar 24. Breast. 2014. PMID: 24675394 Free article. Clinical Trial.
Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
Rordorf T, Hassan AA, Azim H, Alexandru E, Er O, Gokmen E, Güral Z, Mardiak J, Minchev V, Peintinger F, Szendroi M, Takac I, Tesarova P, Vorobiof D, Vrbanec D, Yildiz R, Yücel S, Zekri J, Oyan B; Central European Cooperative Oncology Group (CECOG); Swiss Group for Clinical Cancer Research (SAKK). Rordorf T, et al. Among authors: tesarova p. Breast. 2014 Oct;23(5):511-25. doi: 10.1016/j.breast.2014.05.023. Epub 2014 Jun 27. Breast. 2014. PMID: 24986766 Free article.
61 results